Diabetic complications were diagnosed by the attending physicians according to the Treatment Guide for Diabetes 2010The end‐points of the present study were as follows: (i) the percentage of patients with hypoglycemia based on physician‐recognized hypoglycemia; (ii) the relationship between the percentage of patients with hypoglycemia and characteristics of patients, use of concomitant antidiabetic drugs, complications, and glycemic control; (iii) the relationship between the percentage of patients with hypoglycemia and hypoglycemic symptoms; and (iv) the assessment of the knowledge and attitude of patients regarding hypoglycemia.In total, 6,012 patients with type 2 diabetes mellitus were enrolled at 1,502 clinical sites during the study period. l�2�L��'�H�h��`S �� 9 "K��l/�W 6� Our previous study showed that SU is still prescribed to >30% of elderly patients with type 2 diabetes mellitusThe treatment guidelines for diabetes issued by the Japan Diabetes SocietyAlthough the awareness of hypoglycemia tended to be lower in the elderly subgroups, it tended to increase from baseline to week 52 of the administration of sitagliptin in all age subgroups. As a countermeasure to prevent hypoglycemia, 71.2% of insulin users always carried or intended to carry glucose at baseline (Fig.
The frequency of hypoglycemia and knowledge of hypoglycemia were analyzed using a questionnaire.In total, 5,130 patients (aged 73.8 ± 6.1 years) were analyzed. Because there is a need for dosage adjustment based upon renal function, assessment of renal function is recommended prior to initiation of JANUVIA and periodically thereafter. Among them, 882 patients were excluded from the analysis due to serious violations of the prespecified inclusion/exclusion criteria or protocol, duplicated registration, incomplete case report forms, withdrawal, or no visit after enrollment. This study was registered at the University Hospital Medical Information Network Clinical Trial Registry (UMIN000009332), a non‐profit organization in Japan that meets the requirements of the International Committee of Medical Journal Editors. Clinical data and biomarkers were collected at baseline (week 0) and week 52 after the start of sitagliptin therapy. All personal information was anonymized.
However, the majority of the institutions that participated were clinics or small‐scale hospitals. 248 0 obj <>/Filter/FlateDecode/ID[<40345DE32BD0FB48B1B53F947CFA866E><7D299D6DCD2931459377DF6289BAB35D>]/Index[216 69]/Info 215 0 R/Length 138/Prev 393651/Root 217 0 R/Size 285/Type/XRef/W[1 3 1]>>stream
The improvement of attitude was less in the elderly subgroups, probably because elderly patients tend to have a stronger status quo bias and a change in attitude is more difficult.
(a) Awareness of hypoglycemia in different age subgroups.
284 0 obj <>stream 0 Outpatients with type 2 diabetes mellitus were approached to participate in this study from December 2012 to November 2014. %%EOF h�b```�U�r�� ������Z�9ޖ7�0�-(ِ��� �`��5���@Թ3�V�� Therefore, the study protocol was revised to include patients who used glinides.Sitagliptin (12.5–100 mg) was administered once daily to patients who met the aforementioned criteria, depending on the patient's condition for 52 weeks.
This study was carried out according to the Declaration of Helsinki and current legal regulations in Japan. However, hypoglycemia occurred more frequently with add‐on therapy to SU or when the sitagliptin dose was increased in the combination therapy, showing that sitagliptin should be used with caution.This study was carried out using the research fund of the Japan Physicians Association. ����`��V 6�; Among patients treated with the combination therapy of sitagliptin and insulin at week 52, no other oral hypoglycemic agents had a significant effect on the percentage of patients with hypoglycemia. Sitagliptin is a medicine used to treat type 2 diabetes.Type 2 diabetes is an illness where the body does not make enough insulin, or the insulin that it makes does not work properly.